GlowSense R&D activities are registered under the Australian R&D Tax Incentive (RDTI) programme and grounded in published academic literature — not marketing hypotheses. Every OPP claim is traceable to a DOI.
Australian R&D Tax Incentive
PubMed-indexed foundations
AU 2026901796 · One Pot Process (OPP) Method
6 global jurisdictions searched
Formulation optimisation ongoing
GlowSense's R&D activities are formally registered under the Australian Government's R&D Tax Incentive (RDTI) programme, administered by the Australian Taxation Office (ATO) and AusIndustry. Our RDTI adviser is RADBE Consulting (adviser James Eddy).
RDTI registration provides a 43.5% refundable tax offset on eligible R&D expenditure for companies with aggregated turnover below $20M — creating a direct government co-investment in GlowSense's research programme. Registered R&D activities include the OPP Method development, active stability studies, spicule sizing and characterisation, and transdermal delivery efficacy benchmarking.
Financial and Labour Information (FLI) reporting has been prepared and the programme is structured to maximise eligible core and supporting R&D activity claims. Formal RDTI claim submission is managed by RADBE Consulting on behalf of GlowSense.
The OPP Method is grounded in published scientific literature. The primary evidence base for Haliclona sp. spicule transdermal delivery is peer-reviewed, PubMed-indexed, and reproducible. GlowSense's patent builds on this published science with a novel application — the cold-process single-vessel co-formulation technique — confirmed as having zero global prior art.
Key findings: Haliclona sp. spicules (SHS) — siliceous oxeas, ∼120 µm length, ∼7 µm diameter — physically disrupt skin in a dose-dependent manner and are retained for over 72 hours. SHS enhanced FD-10 (10 kDa fluorescent dextran) penetration into porcine skin by 33.09 ± 7.16-fold (p < 0.01) in vitro and by 72.14 ± 48.75-fold in BALB/c mice in vivo (p < 0.05). Dermis accumulation increased 62.32 ± 13.48-fold vs. control. TEWL studies confirm skin disruption is self-limiting and fully recoverable. SHS outperformed Dermaroller microneedling by 15.39-fold in vivo.
→ View on PubMedKey findings: Comparison of five marine sponge spicule species confirms Haliclona sp. spicules are optimal for skin penetration enhancement, with enhancement magnitude correlating positively with spicule aspect ratio (L/D). For insulin (INS) — a hydrophilic therapeutic peptide — SHS dramatically increased transdermal flux to 457.0 ± 32.3 ng/cm²/h vs. passive penetration of only 5.0 ± 2.2 ng/cm²/h in vitro. Confirms applicability to peptide-class actives directly relevant to the OPP Method.
→ View on PMCKey findings: Clinical validation of spicule-mediated transdermal delivery in human subjects. Transdermal penetration efficiency significantly higher in nano-coated spicule group than uncoated secretome control. Dermal absorption rate measured at 73.4%. Confirms the spicule delivery platform translates from animal models to human clinical outcomes — directly supporting the OPP Method's biological mechanism.
→ View on PMCProvisional patent AU 2026901796 filed 5 March 2026. 19 SOPA items, 11 restructured claims. Zero global prior art confirmed. Voluntary amendments filed via IP Australia eServices.
Preliminary bench work completed to characterise Haliclona sp. spicule sizing (100–400 µm range), purity and morphological verification using available lab microscopy. Compound microscope acquisition (AmScope) identified as next capital investment for advanced bio-spicule characterisation and investor-grade microscopy content.
Full Batch Manufacturing Record (BMR) developed for CS3 SPF50+ Moisturiser trial batch. Homogenisation using AN.GNI AE300L-H rotor-stator homogeniser (borrowed). Process parameters including speed, duration and temperature profiles being documented for GMP compliance.
GS-003 (Niacinamide 10% + Peptide Serum) and GS-004 (SAP Vitamin C 3% Serum) formulation dossiers complete. Stability testing protocols and CoA frameworks in development. Targeting pilot batch production for DTC launch Q3 2026.
HPLC-based quantitative validation of active ingredient stability pre/post OPP co-formulation — planned as next-phase analytical validation to support stronger clinical claims and investor documentation. Currently at preliminary bench level.
OPP Method extension to cream and water-in-oil moisturiser formats using cold-process self-emulsifying systems (Aristoflex AVC, BTMS-based). Extends OPP applicability beyond gel and serum formats to the larger moisturiser market segment.
March 2027 PCT deadline is a fixed milestone in the 6-phase global IP roadmap. Targeting international protection across US, EU, UK, Japan and South Korea — enabling global licensing programme launch post-grant.
We welcome research partnerships, co-development enquiries, and investor due diligence requests. All technology discussions are covered by NDA.